1,175.00
+1.21%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Senores Pharmaceuticals
Its shares trade on NSE under the ticker SENORES.NS. It has been listed since 30 December 2024.
Senores Pharmaceuticals Ltd is a IN-based company operating in industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2024-12-30. Senores Pharmaceuticals Limited is an India-based pharmaceutical company. The firm manufacture products of international quality to cater to the increasing new age demands of the global healthcare industry. The firm's products include Amphetamine Sulfate Tablets USP, 5 mg and 10 mg; Hydroxychloroquine Sulfate Tablets USP, 200 mg; Ketoconazole Tablets USP, 200 mg; Chlorzoxazone Tablets USP, 250 mg; 5Chlorzoxazone Tablets USP, 500 mg; Ketorolac Tromethamine Tablets USP, 10 mg; Diclofenac Potassium Tablets USP, 25 mg; Diclofenac Potassium Tablets USP, 50 mg, and others. The company supplies affordable APIs to generic formulations manufacturers. Its product API include Anastrozole, Aripiprazole, Benfotiamine, Clomiphene Citrate, Desloratadine, Desvenlafaxine Succinate, Fluoxetine Hydrochloride, and others. Its domestic portfolio includes Azithromycin for Injection; Meropenem Injection; Ferric Carboxymaltose Injection; Meropenem and Sulbactam for Injection, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 30 Dec 2024
- Website
- senorespharma.com ↗
Leadership
Pay as last reported
- Mr. Sanjay MajmudarNon-Executive Non-Independent Chairman of the Board
- Mr. Deval ShahChief Financial Officer, Whole Time Director, since 2020₹5.6m
- Mr. Chetan ShahChief Operating Officer, Whole Time Director₹4.3m
- Ms. Nidhi KapadiaCompliance Officer, Company Secretary₹170,000
- Mr. Deepak JainVice President - Regulatory Affairs₹6.8m
- Mr. Swapnil ShahManaging Director, Executive Director₹8.9m
- Mr. Malay PatelAssistant Vice President - Research and Development₹300,000
- Mr. Parag ShahAssistant Vice President - Finance₹6.8m
- Mr. Hanuwant ShaktawatAssistant Vice President - Human Resources and Admin₹1.9m
- Mr. Ashokkumar BarotNon-Executive Non-Independent Director
- Mr. Hemanshu PandyaNon-Executive Non-Independent Director
- Mr. Jitendra SanghviNon-Executive Non-Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Senores Pharmaceuticals Ltd manufactures international quality products like Amphetamine Sulfate Tablets USP and Hydroxychloroquine Sulfate Tablets USP.
- The company supplies affordable APIs including Anastrozole and Aripiprazole to generic manufacturers in India.
- Senores Pharmaceuticals has a domestic portfolio featuring Azithromycin for Injection and Meropenem Injection.
Weaknesses
- The company's product range includes Chlorzoxazone Tablets USP in 250 mg and 500 mg strengths.
- Senores Pharmaceuticals Limited focuses on specific API products like Desloratadine and Desvenlafaxine Succinate.
- The firm's global healthcare industry focus requires continuous innovation for new age demands.
Opportunities
- Senores Pharmaceuticals targets the growing global healthcare industry with products like Ketoconazole Tablets USP.
- The company can expand its API supply to more generic manufacturers in India.
- Senores Pharmaceuticals has potential in the domestic market with Ferric Carboxymaltose Injection.
Threats
- The company faces competition from other pharmaceutical firms in the Indian market.
- Senores Pharmaceuticals must comply with international quality standards for global healthcare demands.
- The firm's reliance on specific product lines like Diclofenac Potassium Tablets USP could pose risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.